Semax is a synthetic heptapeptide analog of ACTH(4-10) that was developed in Russia, where it has been sufficiently studied as an experimental nootropic compound in laboratory models for its neuroprotective and cognitive-modulating properties.
It is made up of the sequence Met-Glu-His-Phe-Pro-Gly-Pro and is usually sold in lyophilized vials for laboratory research purposes. Animal models, as well as a few trials in humans, have indicated that Semax increases expression of BDNF and promotes neuronal plasticity, protects against oxidative stress, and improves attention, memory, and adaptation to stress.
Studies indicate that Semax regulates the expression of genes related to immune response, vascular physiology, as well as neurotrophic signalling pathways, especially in models of cerebral ischemia and experimental markers of Alzheimer-like pathology and cognitive deficits. It has not been FDA-approved for any therapeutic use and is an investigational research compound in the United States.
Looking To Get Started with Researching Semax? Order Now!
How Does Semax Work? Research Studies & Findings
The mechanisms of action via which Semax works are predominantly neurological. When applied intranasally, it passes through the blood-brain barrier quickly and directly interacts with central structures.
Studies show that Semax induces upregulation of brain-derived neurotrophic factor (BDNF) and its receptor TrkB in the hippocampus and other areas, enhancing synaptic plasticity/long-term potentiation.
It also modulates neurotransmitter systems, including serotonin and dopamine, without significant hormonal disruption. Under ischemia-reperfusion, Semax regulates vascular function-related and immune response/inflammation control gene signatures to limit neuronal damage/allow recovery.
Semax helps to decrease oxidative stress by stabilizing mitochondrial activity and suppressing excitotoxicity. It moderates enkephalin and serotonin pathways, being involved in stress adaptation and reduction of anxiety-like behaviour in animal models. Genome-wide transcriptional analyses in rat brain ischemia models demonstrate that Semax has a broad influence on genes associated with neuroprotection, angiogenesis, and tissue remodeling.
These features make Semax a candidate for cognitive enhancement, neuroprotection, and recovery processes within lab conditions.
Semax Benefits (Backed by Research)
Semax has been studied in a number of preclinical and early-phase clinical studies. Key observations from studies include:
1. Enhances Cognitive Performance Markers
In behavioral models, Semax enhances attention and short-term memory and facilitates learning. Studies in rodents demonstrate accelerated conditioned responding, improved maze performance and enhanced object recognition with high doses of dopamine. Evidence from human pilot data shows that these changes in electric fields correlate with changes in EEG, which suggests better cognitive processing.
2. Neuroprotective in Ischemia and Stroke Models
In rat focal cerebral ischemia models, Semax decreases infarct volume, protects neuronal integrity and accelerates the functional recovery. Specifically, it reduces oxidative damage, inflammation and excitotoxicity, which enables better motor performance after injury.
3. Supports BDNF and Neurotrophic Pathways
The semax–BDNF pathway needs not any further justification, as the research performed by Zendulov et al. ASDS029839 has demonstrated that Semax upregulates BDNF and TrkB expression in the hippocampus associated with synaptic plasticity, dendritic remodeling and neuronal survival. This promotes long-term cognitive resilience and memory consolidation in experimental paradigms.
4. Modulates Stress and Anxiety-Related Responses
Studies conducted in animal models exposed to stress revealed that Semax administration decreased anxiety-like behavior and restored the levels of enkephalins and serotonin. It enhances coping with chronic stress and promotes emotional stability in behavioral tests.
5. Helps Recovery from Brain Injury and Neurodegeneration Models
Semax rapidly accelerates the functional recovery and decreases edema, glial activation, and enhances tissue remodeling in models of traumatic brain injury as well as Alzheimer ‘s-like pathology 22–25 Picap — decreases post-resuscitation states: accelerates physical return to normalcy, reduces cerebral damage markers. This demonstrates efficacy in reversing pathological deficits in transgenic models of Alzheimer’s disease.
Disclaimer: All these benefits are specific to research studies or animal models. Semax is not approved for human consumption by the FDA.
Start Your Online Peptide Therapy Now
Semax Dosage Guide: In Research Environment
Semax is available as lyophilized powder (for example 10 mg or 30 mg vials) and is reconstituted for use in laboratory research. In these studies, the use of low doses serves to deliver specific pathway activation with limited non-specific effects.
1. Standard Quantitative Range
- Potent doses in rodent models: 50–600 μg/kg (intranasal systemic)
- 100–300 μg/kg per administration (common research range)
- Goal: Induction of effective neurotrophic signaling and behavioral changes without overstimulation
2. Initial Calibration (Baseline Phase)
- Initial dosing: Lower limit (eg, 50–100 μg/kg intranasal)
- Dosage: One time or multiple times at a low dose
- Rationale: Create a dose-response curve, track immediate behavioral or biochemical changes, and avoid desensitization.
3. Maintenance and Longitudinal Observation
- Target: 200–500 μg/kg (~) daily or every other day
- Time scale: 5–14 days in chronic models, up to 4–8 weeks in longitudinal studies
- Rationale: Steady-state neurotrophic modulation, measure cumulative effects on plasticity, gene expression and behavior
How to Prepare Semax for Research Use
Proper reconstitution and handling ensure peptide stability and experimental accuracy.
1. Supplies Needed Before Mixing
- Vial of the Semax powder (e.g. 10 mg or 30 mg lyophilized)
- Sterile bacteriostatic water or saline
- Alcohol swabs
- A sterile syringe (e.g. insulin syringe)
- Clean, sanitized workspace
2. Step-by-Step Reconstitution Process
- Disinfect vial tops with alcohol swabs.
- Withdraw desired volume of bacteriostatic water into syringe (usually 1–2 mL depending on vial size)
- Inject water as a slow stream down the vial wall to prevent foaming.
- Slowly swirled (not shaken) until completely dissolved, and the solution was clear.
- Store reconstituted vial at 2–8°C, in the original carton to protect from light.
Semax Timeline and Results
Research timelines differ based on model, route, dose and endpoint. Effects are relatively quick due to direct CNS action.
Phase 1: Initial Response (1–7 Days)
- BDNF is upregulated under acute conditions and neurotransmitter modulation
- Observable markers of attention, stress response, and acute neuroprotection
- Inflammatory and plasticity-related proteins are some of the first differentially regulated genes.
Phase 2: Building new patterns into the structure (1–3 weeks)
- Increased synaptic plasticity and dendritic remodeling
- Improvements in memory retention and learning performance on behavioral tests
- Inhibition of oxidative stress and inflammatory markers in injury models
Phase 3: Maturation and Optimization (4–8 Weeks)
- Maximum neurotrophic and cognitive effects
- Durable behavioral effects in models of chronic stress or injury
- Optimal neuroprotection and long-term functional improvement
Step 4: Longitudinal Maintenance and Stability
- With stable dosing, ongoing pathway support
- In some models, the prevention of regression upon withdrawal
- prolonged modulation of gene expression and neuronal resilience
Referenced Studies
1. https://pubmed.ncbi.nlm.nih.gov/16996037/
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC3987924/
3. https://pmc.ncbi.nlm.nih.gov/articles/PMC7350263/
4. https://pubmed.ncbi.nlm.nih.gov/18644225/
5. https://pmc.ncbi.nlm.nih.gov/articles/PMC2787983/
